About Dermapharm Holding SE

Company Description

Dermapharm is a rapidly growing manufacturer of branded pharmaceuticals. Founded in 1991, the Company is based in Grünwald near Munich. The Company's integrated business model comprises in-house development, production and the distribution of brand products by a trained pharmaceutical sales force. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations in Europe (primarily in Germany) and the United States.

In the "Branded pharmaceuticals and other healthcare products" segment, Dermapharm has approximately 1,300 marketing authorisations with more than 380 active pharmaceutical ingredients. Dermapharm's portfolio of pharmaceuticals, medical devices and food supplements are tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany.

Year founded

1991

Served area

Europe + North America

Headcount

2,373

Headquarters

Lil-Dagover-Ring 7, 82031 Grünwald – Germany

Publications

Insider Trades

Date Trading entity / Person Association Trade type Volume Average price
13.01.23 NEON Equity AG Close relation Buy 16,897.00 € 13.01.23
11.01.23 Dreibholz, Christof Board Buy 49,638.00 € 11.01.23
17.10.22 Riedel, Oliver Board Buy 8,650.00 € 17.10.22
17.10.22 Weidenmann, Ralph Supervisory board Buy 2,638.25 € 17.10.22
17.10.22 Riedel, Oliver Board Buy 11,013.18 € 17.10.22
14.10.22 Feldmeier, Dr. Hans-Georg Board Buy 98,900.00 € 14.10.22
13.10.22 Themis Beteiligungs-Aktiengesellschaft Close relation Buy 55,825,000.00 € 13.10.22
13.10.22 Kellinghusen, Dr. Georg Supervisory board Buy 4,884.80 € 13.10.22
22.07.21 Neumeyer, Hilde Board Buy 163,938.30 € 22.07.21
22.07.21 Wahl, Dr. Albert Board Buy 8,514.00 € 22.07.21

Shareholder information

Shares outstanding

53,840,000

IPO

Feb. 9, 2018

Designated Sponsor(s)

Stifel Europe Bank AG, Joh. Berenberg, Gossler & Co. KG

Stock exchange(s)

Frankfurt Stock Exchange

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.